Modality
Fusion Protein
MOA
RAS(ON)i
Target
B7-H3
Pathway
Notch
CLLWilmsCTCL
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
~Aug 2019
→ ~Nov 2020
Phase 2
Feb 2021
→ Aug 2030
Phase 2Current
NCT07281983
2,729 pts·Wilms
2021-02→2030-08·Active
2,729 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-254.4y awayPh2 Data· Wilms
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Active
Catalysts
Ph2 Data
2030-08-25 · 4.4y away
Wilms
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07281983 | Phase 2 | Wilms | Active | 2729 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK |